NEWS

Our Latest News

ARCHIMED acquires cell line development pioneer ExcellGene to accelerate expansion into biosimilars and high-performance transfection solutions

Global private equity healthcare specialist ARCHIMED acquires a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting (both in the biologic therapeutics sector), partnering with founders and management, to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins, and other advanced therapeutics.